Evidence map›Paper›PMID 39159576›Full record

ArticleSeminars in arthritis and rheumatism2024

Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: An international study from the OMERACT myositis working group.

Ellen Romich, Didem Saygin, Dana DiRenzo, Christopher A Mecoli, Ingrid de Groot, Karin Lodin, Malin Regardt, Catherine Sarver, Ju Yeon Kim, Jin Kyun Park and 7 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Seminars in arthritis and rheumatism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ellen RomichDivision of Rheumatology, Department of Medicine, University of Pennsylvania, USA. Electronic address: ellen.romich@pennmedicine.upenn.edu.
Didem SayginDivision of Rheumatology, Department of Medicine, University of Pittsburgh, USA.
Dana DiRenzoDivision of Rheumatology, Department of Medicine, University of Pennsylvania, USA.
Christopher A MecoliDivision of Rheumatology, Department of Medicine, Johns Hopkins University, USA.
Ingrid de GrootPatient Research Partner, the Netherlands.
Karin LodinDivision of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University, Stockholm, Sweden.
Malin RegardtDepartment of Neurobiology, Care Sciences and Society, Division of Occupational Therapy, Karolinska Institutet and Medical Unit Occupational Therapy and Physical Therapy, Karolinska University Hospital, Stockholm, Sweden.
Catherine SarverPatient Research Partner, USA.
Ju Yeon KimDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, South Korea.
Jin Kyun ParkDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, South Korea.
Kelly BeerDepartment of Neurology, Fiona Stanley Hospital, IIID Murdoch University and University of Notre Dame, Perth, Australia.
Merrilee NeedhamDepartment of Neurology, Fiona Stanley Hospital, IIID Murdoch University and University of Notre Dame, Perth, Australia.
Helene AlexandersonMedical Unit Occupational Therapy and Physical Therapy, Karolinska University Hospital and Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Lisa Christopher-StineDivision of Rheumatology, Department of Medicine, Johns Hopkins University, USA.
Marianne de VisserDepartment of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Joost RaaphorstDepartment of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
OMERACT Myositis Working Group

Funding

Training Program/Rheumatic DiseasesT32AR076951 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI EDWARD M BEHRENS, Peter A Merkel · 2020 to 2026
$2.6M
Optimizing the Approach to Identify Cancer-Associated MyositisK23AR075898 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI MECOLI, CHRISTOPHER · 2019 to 2023
$773k
NIAMS NIH HHS K23 AR075898NIAMS NIH HHS T32 AR076951
6 · The paper itself

Abstract

backgroundValidated patient-reported outcome measures to assess disease impact in patients with adult idiopathic inflammatory myopathies (IIMs) are needed. The objective of this study was to assess the construct validity of PROMIS Pain Interference, Fatigue, and Physical Function measures in comparison with core disease activity measures.

methodsAdults with IIM, excluding inclusion body myositis, from OMERACT Myositis Working Group (MWG) clinic sites completed PROMIS Short Form v1.0-Pain Interference 6a, PROMIS Short Form v1.0-Fatigue 7a, and PROMIS Short Form v2.0-Physical Function 8b measures. Core disease activity measures including patient and physician global disease activity assessments, manual muscle testing, serum creatine kinase activity, and Health Assessment Questionnaire Disability Index (HAQ-DI) were simultaneously assessed. To evaluate construct validity, a priori hypotheses for the expected correlations between PROMIS measures, age, and core disease measures were determined by >70 % agreement among MWG members and were compared against observed Pearson's correlations. Internal consistency of items and floor or ceiling effects for the PROMIS measures were also assessed. Subgroup analysis according to IIM subtype (dermatomyositis vs. non-dermatomyositis IIM) was performed.

results135 adults with IIM from 5 countries across North America, Europe, Asia, and Australia were included. For construct validity, a priori hypotheses were confirmed for 5 of 6 (83 %) PROMIS Pain Interference, 4 of 5 (80 %) PROMIS Fatigue, and 3 of 4 (75 %) PROMIS Physical Function correlations. Internal consistency was high for each PROMIS measure (Cronbach's alpha >0.9). Ceiling effects were observed only for PROMIS Pain Interference, with low/no pain in 29 % of patients. Subgroup analysis between dermatomyositis (n = 65) and non-dermatomyositis (n = 70) subtypes demonstrated similar correlations between PROMIS measures and disease activity measures.

conclusionsPROMIS Short Form v1.0-Pain Interference 6a, PROMIS Short Form v1.0-Fatigue 7a, and PROMIS Short Form v2.0-Physical Function 8b measures demonstrate strong construct validity when compared to core disease activity measures in IIM, with consistent results across IIM subtypes. These findings support the use of these selected PROMIS measures to assess core domains of interest for measuring life impact in IIMs.

Indexed as

FatigueMyositisPatient Reported Outcome MeasuresAdultAgedDisability EvaluationFemaleHumansMaleMiddle AgedPainPain MeasurementReproducibility of ResultsSeverity of Illness IndexMyositisOMERACTOutcome measurementPatient-reported outcomeQuality of life Measure

Identifiers

PMID39159576
PMCPMC11404521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.